LENZ Therapeutics (NASDAQ:LENZ) & Novo Nordisk A/S (NYSE:NVO) Financial Contrast

LENZ Therapeutics (NASDAQ:LENZ) and Novo Nordisk A/S (NYSE:NVO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for LENZ Therapeutics and Novo Nordisk A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	5	0	2.50
Novo Nordisk A/S	1	14	3	0	2.11

LENZ Therapeutics currently has a consensus target price of $28.80, suggesting a potential upside of 645.15%. Novo Nordisk A/S has a consensus target price of $64.94, suggesting a potential upside of 69.49%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe LENZ Therapeutics is more favorable than Novo Nordisk A/S.

Earnings and Valuation

This table compares LENZ Therapeutics and Novo Nordisk A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	6.36	-$82.13 million	($4.09)	-0.94
Novo Nordisk A/S	$46.80 billion	3.66	$15.51 billion	$4.09	9.37

Novo Nordisk A/S has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LENZ Therapeutics and Novo Nordisk A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Novo Nordisk A/S	35.36%	58.61%	20.91%

Volatility & Risk

LENZ Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Institutional and Insider Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Novo Nordisk A/S beats LENZ Therapeutics on 8 of the 14 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.